Progressive Supranuclear Palsy Diagnostic Methods

Overview

Progressive Supranuclear Palsy (PSP) is a 4R-tauopathy characterized by progressive postural instability, vertical supranuclear gaze palsy, and cognitive impairment. Accurate diagnosis remains challenging, particularly in early disease stages, due to clinical overlap with Parkinson’s disease (PD), Corticobasal Syndrome (CBS), and other parkinsonian disorders. This page details current diagnostic approaches, including clinical criteria, imaging biomarkers, CSF analysis, and differential diagnosis.

Clinical Diagnostic Criteria

Movement Disorder Society-PSP Criteria (MDS-PSP 2017)

The MDS-PSP criteria represent the current standard for PSP diagnosis, providing four phenotypic subtypes with varying levels of diagnostic certainty:

Level	Description
Probable PSP	Core clinical features present with no alternative explanation
Possible PSP	Core or suggestive features present but with some uncertainty
Suggestive of PSP	Fewer or less specific features, requiring imaging support
Laboratory-supported PSP	Specific biomarker findings supporting diagnosis

Core Clinical Features

Vertical supranuclear gaze palsy (VSGP) — Cardinal feature; downward gaze impairment is most specific
Postural instability with falls — Within first year of symptoms predicts PSP-P (parkinsonian variant)
Progressive gait freezing — Early gait ignition failure and freezing
Cortical dysfunction — Frontal lobe signs including apathy, disinhibition, executive dysfunction

Suggestive Features

Early dysphagia and dysarthria
Early cognitive impairment with frontal lobe pattern
Levodopa-unresponsive parkinsonism
Myoclonus (especially in PSP-CBS)
Alien limb phenomena

Clinical Subtypes

Subtype	Core Features	Typical Presentation
PSP-Richardson’s (PSP-RS)	VSGP + postural instability	Classic Richardson’s syndrome
PSP-Parkinsonism (PSP-P)	Asymmetric onset, tremor, levodopa response	May resemble PD initially
PSP-Pure Akinesia with Gait Freezing (PSP-PAGF)	Gait freezing without VSGP	Longer disease duration
PSP-Corticobasal (PSP-CBS)	Cortical sensory loss, apraxia	Overlaps with CBS
PSP-Frontal (PSP-F)	Predominant frontal dysfunction	Behavioral variant
Primary Progressive Aphasia (PSP-PPA)	Language dysfunction	Rare variant

Imaging Biomarkers

Magnetic Resonance Imaging

Conventional MRI Findings

Midbrain atrophy: “Hummingbird sign” on midsagittal views
Superior cerebellar peduncle atrophy: “Mickey Mouse sign”
Third ventricle enlargement
Frontotemporal cortical atrophy

Quantitative MRI Techniques

MR planimetry: Midbrain/pons area ratio <0.52 suggests PSP
Magnetic Resonance Parkinsonism Index (MRPI): Elevated in PSP vs. PD
Free water imaging: Elevated in substantia nigra and pedunculopontine nucleus

SWI (Susceptibility-Weighted Imaging)

Tau-related changes: Reduced contrast in red nucleus and substantia nigra
Iron deposition patterns: Differentiate PSP from PD

Nuclear Medicine Imaging

DAT Imaging (DaTscan/I-123 FP-CIT)

Presynaptic dopamine transporter loss: Typically more severe in PSP than PD
Pattern analysis: Caudate involvement more prominent in PSP

FDG-PET

Metabolic patterns: Hypometabolism in prefrontal cortex, brainstem, and cerebellar hemispheres
Differential patterns: PSP shows midbrain and frontal hypometabolism; PD shows putaminal changes

Tau PET Imaging

F-18 AV-1451 (Flortaucipir): Binds to paired helical filament tau
Preliminary findings: Elevated binding in PSP brainstem and subcortical structures
Clinical utility: Currently research use only

CSF Biomarkers

Established Markers

Biomarker	PSP Finding	Clinical Utility
Neurofilament light chain (NfL)	Elevated	High sensitivity for neurodegeneration
Total tau (t-tau)	Normal to mildly elevated	Differentiates from AD
Phosphorylated tau (p-tau)	Normal or mildly elevated	Distinguishes from AD
Alpha-synuclein	Normal	Rules out MSA-P, PD
Beta-amyloid 1-42	Normal	Rules out AD comorbidity

Emerging Biomarkers

Tau oligomers: Elevated in PSP vs. controls
Neurogranin: Marker of synaptic dysfunction
YKL-40 (Chitinase-3-like protein 1): Astrocytic activation marker
TREM2: Microglial activation marker

Differential Diagnosis

Parkinson’s Disease (PD)

Feature	PSP	PD
Eye movements	VSGP early	Late or absent
Postural instability	Early (within 1 year)	Late (after 5+ years)
Tremor	Less common	Common, resting tremor
Levodopa response	Poor	Good initially
Progression	Rapid	Slow

Corticobasal Syndrome (CBS)

Overlap: PSP-CBS phenotype shares features
Key differences: Asymmetric onset, apraxia, cortical sensory loss favor CBS
Tau pathology: Both are 4R-tauopathies; post-mortem required for definitive diagnosis

Multiple System Atrophy (MSA-P)

Autonomic dysfunction: More severe in MSA
Cerebellar signs: Favor MSA-C variant
Imaging: Hot cross bun sign in MSA

Alzheimer’s Disease

Memory impairment: More prominent in AD
Amyloid biomarkers: Positive in AD, negative in PSP
Tau PET: Different binding patterns

Diagnostic Workflow

flowchart TD
    A["Patient with Parkinsonian Symptoms"] --> B{"Clinical Evaluation"}
    B --> C["VSGP Present?"]
    C -->|"Yes"| D["Postural Instability <1 year?"]
    C -->|"No"| E["Other Core Features?"]
    D -->|"Yes"| F["Probable PSP"]
    D -->|"No"| G["Possible PSP - Order MRI"]
    E -->|"Yes"| H["MRI Findings Consistent?"]
    E -->|"No"| I["Consider Other Diagnoses"]
    H -->|"Yes"| J["Possible PSP with Imaging Support"]
    H -->|"No"| K["Follow Clinical Progression"]
    F --> L["Order Supportive Tests"]
    J --> L
    L --> M["DAT Scan, MRI, CSF"]
    M --> N["Integrate Findings"]
    N --> O["Final Diagnosis"]